Catalyst Pharmaceuticals (CPRX) Gross Profit (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Gross Profit data on file, last reported at $134.9 million in Q1 2026.

• Quarterly Gross Profit rose 9.23% year-over-year to $134.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $513.1 million (up 11.45% YoY) and the FY2025 annual result came in at $501.7 million, up 18.64% from the prior year.
• Gross Profit climbed to $134.9 million in Q1 2026, from $126.5 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $134.9 million in Q1 2026 to a low of $37.2 million in Q1 2022.
• A 5-year average of $93.3 million and a median of $94.8 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit surged 102.75% — and 2025, when it grew 5.29%.
• Tracing CPRX's Gross Profit over 5 years: stood at $49.6 million in 2022, then jumped by 91.19% to $94.8 million in 2023, then gained by 26.82% to $120.2 million in 2024, then grew by 5.29% to $126.5 million in 2025, then increased by 6.62% to $134.9 million in 2026.
• The last three Gross Profit figures came in at $134.9 million (Q1 2026), $126.5 million (Q4 2025), and $125.7 million (Q3 2025), per Business Quant data.